Vimarsana
Biggest News Aggregation in the World

Page 2 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Hold" by Analysts - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Hold" by Analysts

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has received an average rating of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average […]

TCG Crossover Management LLC Grows Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Vimarsana News

TCG Crossover Management LLC Grows Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

TCG Crossover Management LLC boosted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) by 2.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,276,574 shares of the company’s stock after buying an additional 26,574 shares during the period. C4 Therapeutics […]

Source: wkrb13.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.33 Consensus Target Price from Analysts - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.33 Consensus Target Price from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating […]

Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $9.33 - Vimarsana News

Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $9.33

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average rating of “Hold” by the seven ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating […]

Source: wkrb13.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of "Reduce" from Brokerages - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of "Reduce" from Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have earned a consensus rating of “Reduce” from the six research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the […]